The short answer
Do not add a concentrated bitter-orange supplement to phenelzine without your prescriber's review. A blood-pressure interaction is plausible, but it has not been established in a direct study of this exact pair. Products differ, and p-synephrine should not simply be treated as identical to ephedrine.
What this answer covers
Oral Citrus aurantium fruit extracts containing p-synephrine or other adrenergic constituents, especially stimulant blends. This does not cover ordinary food portions, aromatic oils, skin use or synthetic m-synephrine.
- Supplement or preparation
- Citrus aurantium
- Medication ingredient
- phenelzine
Why it deserves a product review
Bitter orange is often used in stimulant or weight-management products. With phenelzine, the concern is whether the actual formulation adds adrenergic effects. A label saying "ephedra-free" does not establish that a product is appropriate.
The human studies do not all agree
One small trial found higher blood pressure after a bitter-orange extract. Another found an increase with a multi-ingredient product but not the tested single extract. Neither study included phenelzine, so they cannot measure this interaction.
Keep the chemical identity clear
Naturally occurring p-synephrine is not the same as ephedrine or synthetic m-synephrine. The plant name also does not tell you how much of each constituent is present. A pharmacist needs the full formulation and serving size.
What to do before taking it
Have the product reviewed before use and do not try to compensate by spacing it from phenelzine. Seek urgent help for a sudden severe headache, chest pain or a severe blood-pressure reaction. Do not stop the prescribed medicine to make room for a supplement.
Evidence and practical considerations
Side effects & toxicity
Phenelzine prohibits sympathomimetic agents. Small bitter-orange trials without MAOIs have inconsistent blood-pressure results, including differences between a single extract and a stimulant blend. No exact-pair trial or well-documented case was identified.
- Exact scope
- Oral Citrus aurantium fruit extracts containing p-synephrine or other adrenergic constituents, especially stimulant blends. This does not cover ordinary food portions, aromatic oils, skin use or synthetic m-synephrine. with Oral phenelzine tablets; current sulfate-tablet labeling uses the named active ingredient.
- Medication form and route
- oral
What remains uncertain
- A mechanistic concern is not a demonstrated interaction. The trials were small, acute and formulation-specific; p-synephrine and ephedrine are not pharmacologically identical.
Factors that may matter: Exact supplement preparation and complete concomitant-medication list require assessment..
Read the supporting source summaries
Source 1: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral phenelzine sulfate tablets.
The label prohibits sympathomimetics, L-tryptophan, L-tyrosine, phenylalanine and serotonergic agents. It warns about excessive caffeine and high-tyramine exposures.
How this applies: Primary authority for phenelzine oral-tablet precautions; each article identifies whether the supplement is named or the application is a constituent/class inference.
Regulatory instructions do not quantify an exact-pair event rate or validate every botanical formulation.
Source 2: Federal botanical safety information
nccih.nih.gov · Source check Sep 10, 2026
Population: Users and studies of bitter-orange products.
Cardiovascular findings are inconsistent; p-synephrine differs pharmacologically from ephedrine, and combination products complicate attribution.
How this applies: No exact phenelzine-bitter-orange clinical study; structural similarity alone is not proof of equivalent effects.
No exact phenelzine-bitter-orange clinical study; structural similarity alone is not proof of equivalent effects.
Source 3: Randomized double-blind crossover human trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 15 young healthy adults, not using phenelzine.
Blood pressure and heart rate increased for several hours relative to placebo.
How this applies: Small acute trial of one extract; no MAOI coadministration and no long-term risk estimate.
Small acute trial of one extract; no MAOI coadministration and no long-term risk estimate.
Source 4: Randomized double-blind crossover human trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 10 healthy adult nonsmokers, not a MAOI-treated group.
The multicomponent formulation increased blood pressure; Advantra Z did not, despite greater synephrine exposure. Both increased heart rate at the later measurement.
How this applies: Contrary formulation-specific evidence prevents treating all Citrus aurantium products as equivalent stimulants.
Small single-dose study. Ingredients differ; cannot identify the risk of a specific current product or the exact phenelzine interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial targeted research draft. Inspected source material, adjudicated the current checker statements, and recorded preparation limits. Clinical review has not occurred. | |
| Research summary published |
Article revision: d4b6046c5e26896a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.